...construction ready. It's doubtful that any new production will be able to come online within the next two years - apart from the primary producers, #BMN and $LGO, expanding their operations.
@BushveldMin_Ltd owns two of only four primary production operations worldwide. 2/11
It is incredibly leveraged to the V price, which itself is illiquid and prone to exceptional moves.
With the global economic recovery driving steel output to all-time highs, demand for V (which is primarily used to strengthen steel) is steadily increasing.
3/11
Moreover, the commercialisation of the Vanadium Redox Flow Battery industry is rapidly building up a head of steam - which adds to global demand for V.
Demand increasing, no new supply coming online in the near-term - see the above retweet for what happened to V in 2018...! 4/11
Despite the obvious appealing fundamentals on the pure mining side the biz, I still would not be holding if it were only that to the investment thesis.
Like MKA and TGR, #BMN also has an integrated 'green tech' aspect of its business. It's in the process of manufacturing... 5/11
....an electrolyte plant in SA, which will produce the highly valuable liquid that is the key ingredient of VRFB technology. There are very few of these plants in the world, period.
Furthermore, #BMN has supply agreements with two leading VRFB companies - #IES and Enerox. 6/11
#BMN has also pioneered a V rental agreement, whereby these VRFB manufacturers / owners can lease the V for 20 years or so. This drastically reduces upfront capex of the VRFB, one of the major hurdles at present to global adoption.
This is possible because the V in a... 7/11
...VRFB is recyclable, even after 20 years and the battery itself has reached end of life. The V can be extracted by #BMN and then sold into the steel industry.
Essentially, @BushveldMin_Ltd will create an annuity-esque revenue stream, growing steadily year-on-year...
8/11
...with each VRFB installed. And, as a bonus, it gets to sell the material all over again in 20 years.
- One of only 3 pure play V producers worldwide.
- Heavily geared to the very evident price squeeze in V that is now on;
- Trading on sub 5x 2022 EV/EBITDA, at...
9/11
...FeV pricing of only $40/kg (currently $43.3/kg and rising rapidly!);
- Acting as a major catalyst in the growth of the VRFB market, which could become a core industry in the stationary energy storage sector;
- Building out an annuity-esque biz.
- Within 4 years, #BMN... 10/11
...also intends to have doubled V production to 8,400 tonnes pa. At $50/kg, that would amount to $420m revs pa, just from mining (EBIT margin would be 50-60%).
Much, much more to cover about @BushveldMin_Ltd#BMN(!), but I hope this helps as a basic intro for newcomers. 11/11
• • •
Missing some Tweet in this thread? You can try to
force a refresh
ST trade: multiple purchases this week in #AVCT, av. 169p. Separate from core LT hold.
'Bad' news (i.e. slower build up in manufacturing capacity than envisaged by most; no commercial orders yet) now out of the way; potential for major and frequent positive news flow ahead. 1/12
Worst case scenario for #AVCT is that it'll sell 3m to 5m LFTs a month from August, for the next 3 years. That'll be £3m to £5m gross profit per month.
With clinical trials now commencing, assume annual cash burn increases to c.£30m.
@avacta's AVA6000 approved by MHRA. Superb news. First dosing 'around mid-year'; first data to come within 3-4 months after that.
A summary thread on the significance of AVA6000 - and #AVCT's pre CISION platform as a whole - to both the oncology industry and to AVCT itself. 1/10
In very basic terms, #AVCT's pre CISION chemotherapies are essentially reformulated versions of existing, approved chemotherapies that have been used on cancer patients for many years - decades, even.
The pre CISION tech is simply an attempt to improve the safety profile... 2/10
...of the chemo.
Most therapeutics going through clinical trials look for an improvement of at least 20% over the existing industry-standard drug. A 50% increase in efficacy would usually be considered an astonishing result.
In pre-clinical mouse models for #AVCT's AVA6000 3/10
By the end of next week, the Co intends to have put out a comprehensive TU.
Critically, it will include the sensitivity / specificity of its #COVID19 LFT for the first time. Analytical data collected so far suggests that it'll...1/14
...be the most accurate LFT in the world. However, it is not a given that analytical data will be replicated in the clinical data. Likely, but not definite.
Let's assume it IS replicated. #AVCT will CE Mark its LFT next month, and immediately begin selling it.
2/14
@avacta#AVCT does not have its own manufacturing capacity (yet). It will be contracting manufacturers to make its test.
The issue is - as is becoming more and more often the case in the world of micro-caps - people are buying companies like #AVCT without having first decided if it is a trade or an investment position.
I cover the importance of this distinction in my profile picture. 2/n
I myself am a trader, professionally, and actually hold very few long term investments. The volatility and lack of quality, accessible research renders AIM an excellent trading ground.
But @avacta#AVCT is an investment. In the next few weeks, it'll be submitting... 3/n
An extraordinary day. Firstly, fabulous initial data from Pfizer's vaccine, demonstrating it's 90% effective. An immense scientific breakthrough and a boon for humanity.
From an investment perspective (the raison d'être of this account!): a day of joy and misery, equally! 1/16
Global indices absolutely rocketed - 27/100 FTSE100 Cos ended the session at 10%+. Most sectors were up, whilst precious metals miners and #COVID19-centric stocks got obliterated. The latter group included treatment and testing stocks, and at home/online entertainment/living 2/16
Personally, my PF took an almighty spanking, owing to #AVCT being my largest position by a distance, and also having recently opened a position in #SNG.
A high quality vaccine was always the key risk to #COVID19 plays, but for me, that has always been a medium term risk. 3/16
...largely refined. It now need only prove consistent in-vivo success for its three target applications (oncology injection; vaccine injection; vaccine oral), and it can start out-licensing Nuvec.
And that's the core of the investment proposition: Nuvec is a platform tech. 2/4
It can be licensed out to multiple parties for multiple targets/applications. #N4P will receive upfront and milestone payments as the licensee takes the drug / vaccine (using Nuvec as the delivery platform) through the clinic.